Immunovant Market Capitalization from 2010 to 2026
| IMVT Stock | USD 26.65 0.37 1.41% |
Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as Depreciation And Amortization of 322.3 K, Interest Expense of 0.0 or Selling General Administrative of 93.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.0. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.
Immunovant | Market Capitalization | Build AI portfolio with Immunovant Stock |
The evolution of Market Capitalization for Immunovant provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Immunovant compares to historical norms and industry peers.
Latest Immunovant's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Immunovant over the last few years. It is Immunovant's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunovant's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 5.24 B | 10 Years Trend |
|
Market Cap |
| Timeline |
Immunovant Market Capitalization Regression Statistics
| Arithmetic Mean | 1,005,968,010 | |
| Geometric Mean | 903,153,349 | |
| Coefficient Of Variation | 52.10 | |
| Mean Deviation | 449,703,294 | |
| Median | 672,611,404 | |
| Standard Deviation | 524,068,553 | |
| Sample Variance | 274647.8T | |
| Range | 1.3B | |
| R-Value | 0.69 | |
| Mean Square Error | 154629.1T | |
| R-Squared | 0.47 | |
| Significance | 0 | |
| Slope | 71,313,465 | |
| Total Sum of Squares | 4394365.6T |
Immunovant Market Capitalization History
About Immunovant Financial Statements
Immunovant shareholders use historical fundamental indicators, such as Market Capitalization, to determine how well the company is positioned to perform in the future. Although Immunovant investors may analyze each financial statement separately, they are all interrelated. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunovant's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.